<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01343511</url>
  </required_header>
  <id_info>
    <org_study_id>BKCR-AUTISM-1.0(2009)</org_study_id>
    <nct_id>NCT01343511</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Stem Cell Therapy in Patients With Autism</brief_title>
  <official_title>Phase Ι/Π Study of Stem Cell Therapy in Patients With Autism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Beike Bio-Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shandong Jiaotong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Association for the Handicapped Of Jinan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenzhen Beike Bio-Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autism is one of those disorders in Autism spectrum disorders (ASD), which characterized by
      social interaction abnormalities, impaired verbal and non-verbal communication, and
      repetitive, obsessive behavior, while the therapeutic effect of current treatments remains
      limited progress .Neural hypoperfusion and immune deregulation are the two key pathologies
      associated with Autism. Human umbilical cord mesenchymal stem cells (hUC-MSCs) and human cord
      blood mononuclear cells (hCB-MNCs) have been shown to have the ability to modulate the immune
      response and enhance angiogenesis, suggesting the novel and promising therapeutic strategy.
      In this study, the safety and efficacy of hUC-MSCs and hCB-MNCs transplantation will be
      evaluated in patients with Autism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the safety and efficacy of human cord blood mononuclear cells and human
      umbilical cord mesenchymal stem cells transplantation in patients of Autism.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Childhood Autism Rating Scale，CARS</measure>
    <time_frame>6 months after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impression Scale，CGI</measure>
    <time_frame>6 months after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aberrant Behavior Checklist，ABC</measure>
    <time_frame>6 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event and Serious Adverse Event</measure>
    <time_frame>6 months after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Autism</condition>
  <arm_group>
    <arm_group_label>Rehabilitation plus hCB-MNCs treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given rehabilitation therapy plus human cord blood mononuclear cells transplantation with a 6 months follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rehabilitation plus hCB-MNCs and hUC-MSCs therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given rehabilitation therapy plus combination of hCB-MNCs together with hUC-MSCs transplantation with a 6 months follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human cord blood mononuclear cells</intervention_name>
    <description>Participants will be given rehabilitation therapy plus hCB-MNCs transplantation.</description>
    <arm_group_label>Rehabilitation plus hCB-MNCs treatment</arm_group_label>
    <other_name>Group 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells</intervention_name>
    <description>Participants will be given rehabilitation therapy plus and hCB-MNCs and hUC-MSCs transplantation.</description>
    <arm_group_label>Rehabilitation plus hCB-MNCs and hUC-MSCs therapy</arm_group_label>
    <other_name>Group 2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children between the ages of 3 and 12 years.

          -  DSM-IV diagnosis of Autistic Disorder.

          -  Total score of CARS ≥ 30.

          -  Parents or legal guardian willing to sign the ICF.

        Exclusion Criteria:

          -  Any history of hypersensitivity to serum products, or other known drug and food
             allergy.

          -  History of prior or current DSM-IV psychotic disorder (e.g., schizophrenia, bipolar
             disorder, other psychosis), Pervasive Developmental Disorder not otherwise specified
             (PDD NOS), Asperger's, or Rett's.

          -  History of Epileptic seizure activity in the past 6 months.

          -  Autism caused by seizure disorders (active), cerebrovascular disease or brain trauma.

          -  The global autism ratings are assessed as being absent, minimal or mild.

          -  Existing moderate or severe extrapyramidal symptoms (EPS) or history of tardive
             dyskinesia.

          -  Subjects who have displayed significant self-injurious behavior (children who have
             caused visible harm to themselves).

          -  HIV+

          -  Acute and chronic hepatitis.

          -  Autoimmune disease, e.g. lupus erythematosus, multiple sclerosis.

          -  Severe pulmonary and hematological disease, malignancy or hypo-immunity.

          -  Currently undertaking other treatment that may affect the safety/efficacy of stem
             cells.

          -  Enrollment in other trials in the last 3 months.

          -  Other criteria the investigator consider improper for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongtao Lv</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Jiaotong Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shandong Jiaotong Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Liu M, Sun LW, LV YT, Huan Y, Ge RC, Cao YL, Guo CQ, Chen XW. Stem cells for treatment of autism: Safety and efficacy. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2010;14(32): 5967-5970.</citation>
  </results_reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2011</study_first_submitted>
  <study_first_submitted_qc>April 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2011</study_first_posted>
  <last_update_submitted>October 13, 2011</last_update_submitted>
  <last_update_submitted_qc>October 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autism</keyword>
  <keyword>human cord blood mononuclear cells</keyword>
  <keyword>human umbilical cord mesenchymal stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

